4YL Stock Overview
Engages in the provision of nanotechnology and drug particle engineering services for the pharmaceutical and biotech industry in Europe and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Nanoform Finland Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.40 |
| 52 Week High | €3.06 |
| 52 Week Low | €1.08 |
| Beta | 0.80 |
| 11 Month Change | -7.17% |
| 3 Month Change | -16.98% |
| 1 Year Change | -13.70% |
| 33 Year Change | -78.85% |
| 5 Year Change | n/a |
| Change since IPO | -68.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4YL | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 23.1% | 0.9% | -0.02% |
| 1Y | -13.7% | 2.7% | 8.2% |
Return vs Industry: 4YL underperformed the German Life Sciences industry which returned 2.7% over the past year.
Return vs Market: 4YL underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 4YL volatility | |
|---|---|
| 4YL Average Weekly Movement | 7.7% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 4YL's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4YL's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 174 | Edward Haeggstrom | www.nanoform.com |
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharmaceutical and biotech industry in Europe and the United States. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients, as well as designs and develops nanoformed drug substance. It also offers STARMAP, as a secure online portal to perform large numbers of in-silico CESS experiments The company was founded in 2008 and is headquartered in Helsinki, Finland.
Nanoform Finland Oyj Fundamentals Summary
| 4YL fundamental statistics | |
|---|---|
| Market cap | €114.61m |
| Earnings (TTM) | -€23.07m |
| Revenue (TTM) | €2.99m |
38.3x
P/S Ratio-5.0x
P/E RatioIs 4YL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4YL income statement (TTM) | |
|---|---|
| Revenue | €2.99m |
| Cost of Revenue | €521.04k |
| Gross Profit | €2.47m |
| Other Expenses | €25.55m |
| Earnings | -€23.07m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 82.59% |
| Net Profit Margin | -771.06% |
| Debt/Equity Ratio | 0% |
How did 4YL perform over the long term?
See historical performance and comparison